Neoadjuvant progesterone therapy for primary breast cancer: Rationale for a clinical trial

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

The hormonal milieu at the time of surgery may influence mortality and disease-free survival in patients with primary breast cancer. Indeed, there is evidence that circulating unopposed estrogen is detrimental and that the presence of circulating progesterone results in an improved disease-free and overall survival rate. Thus patients who receive neoadjuvant progesterone therapy may have a better outcome. A randomized controlled trial in which women with primary breast cancer receive either progesterone or placebo before surgery is urgently needed to confirm this hypothesis.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
JournalClinical Therapeutics
Volume19
Issue number1
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Keywords

  • estrogen
  • neoadjuvant progesterone
  • primary breast cancer
  • surgery

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Neoadjuvant progesterone therapy for primary breast cancer: Rationale for a clinical trial'. Together they form a unique fingerprint.

Cite this